Illumina, Inc. $ILMN Shares Sold by Jennison Associates LLC

Jennison Associates LLC trimmed its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 4.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 191,907 shares of the life sciences company’s stock after selling 7,951 shares during the period. Jennison Associates LLC’s holdings in Illumina were worth $23,654,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. MassMutual Private Wealth & Trust FSB raised its holdings in Illumina by 7.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock worth $142,000 after purchasing an additional 79 shares during the last quarter. HighPoint Advisor Group LLC raised its stake in shares of Illumina by 3.7% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after buying an additional 80 shares during the last quarter. Toronto Dominion Bank raised its stake in shares of Illumina by 0.3% during the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after buying an additional 92 shares during the last quarter. Panagora Asset Management Inc. boosted its position in shares of Illumina by 3.9% in the 4th quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock worth $333,000 after buying an additional 96 shares in the last quarter. Finally, Venturi Wealth Management LLC grew its stake in Illumina by 4.2% in the 4th quarter. Venturi Wealth Management LLC now owns 2,465 shares of the life sciences company’s stock valued at $323,000 after acquiring an additional 99 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Down 1.1%

Shares of ILMN stock opened at $184.68 on Tuesday. The firm’s 50-day simple moving average is $167.28 and its 200-day simple moving average is $143.77. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. Illumina, Inc. has a 1-year low of $88.00 and a 1-year high of $196.66. The firm has a market cap of $27.94 billion, a P/E ratio of 33.58, a PEG ratio of 3.49 and a beta of 1.47.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. Illumina’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts forecast that Illumina, Inc. will post 5.22 EPS for the current year.

Insider Transactions at Illumina

In other Illumina news, Director Keith A. Meister sold 235,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the completion of the sale, the director owned 2,830,452 shares of the company’s stock, valued at approximately $463,146,860.76. The trade was a 7.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the transaction, the senior vice president directly owned 21,259 shares in the company, valued at $3,456,500.81. This represents a 3.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 1,003,769 shares of company stock valued at $155,710,908. Corporate insiders own 2.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on ILMN shares. Barclays lifted their target price on shares of Illumina from $122.00 to $145.00 and gave the stock an “underweight” rating in a research report on Wednesday, June 24th. Wall Street Zen cut shares of Illumina from a “buy” rating to a “hold” rating in a research note on Saturday. Royal Bank Of Canada started coverage on Illumina in a research note on Thursday, May 14th. They issued an “outperform” rating and a $170.00 target price on the stock. Piper Sandler increased their target price on Illumina from $170.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 1st. Finally, TD Cowen reissued a “hold” rating on shares of Illumina in a report on Wednesday, July 15th. Nine research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $156.88.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.